NEW YORK (Reuters Health) – Medical experts at Mount Sinai Hospital in the United States have successfully tested a new drug that lowers unhealthy body fat, LDL cholesterol, in which it lowers LDL in cholesterol patients. The amount is reduced by 50%.
These were the second phase of medical trials (Phase 2 clinical trials) in which 272 volunteers participated. Details of this success are published online in the latest issue of The New England Journal of Medicine.
Read More:Children’s different immune responses protect them from the severity of corona, research says
Applications have now been submitted to the relevant US and European agencies for approval of the final phase of the drug, ie the third phase of clinical trials, and it is hoped that these trials will begin by next year. If all goes well, the drug is expected to be available in the market by 2023 or 2024.
Called “Evinacumab”, the drug contains “monoclonal antibodies” which are considered to be very promising in modern medicine.
Read More:Expensive filtered masks do not prevent the spread of corona virus, research says
It should be noted that if the amount of LDL cholesterol in the body continues to rise, it accumulates on the inner surface of the veins and obstructs blood flow, leading to an increase in blood pressure and, in the next stage, a heart attack Taxes can cause paralysis.
All participants in the clinical trials had elevated LDL cholesterol and were not significantly affected by current cholesterol medications.
Half of the 272 volunteers were given real medicine, while the other half were given different amounts of synthetic medicine (placebo) in his name. The drug was used in pill form or as an injection.
Volunteers who used 450 mg of Avinacumib in pill form each week had their LDL cholesterol reduced by 56% after 16 weeks. Cholesterol lowering in all volunteers was analyzed based on comparisons with the “placebo group”.
Similarly, volunteers who took 300 mg of the drug as tablets throughout the week had a 52.9% reduction in LDL cholesterol after 16 weeks; It also reduced LDL cholesterol by 38.5% in those who took 300 mg of avinacumab tablets in half a dose, ie 2 weeks.
Injecting patients also benefited greatly. The research report found that volunteers who injected the drug at a dose of 15 mg per kg had a 50.5% lower LDL cholesterol rate, compared to 5 mg per kg. LDL cholesterol decreased by an average of 24.2% among drug users.
The drug is being hailed as an important breakthrough in the treatment of cholesterol, as lowering the amount of cholesterol in the body will go a long way in preventing a number of dangerous and deadly diseases.